VIDEO: Investigator provides update on Port Delivery System
Click Here to Manage Email Alerts
SEATTLE — In this Healio Video Perspective from the ASRS annual meeting, Dennis Marcus, MD, provides an update on the phase 3 Pagoda and Pavilion trials evaluating the Port Delivery System.
According to Marcus, the phase 3 Pagoda and Pavilion trials, which investigated the Port Delivery System with ranibizumab (Genentech), now called Susvimo, for the treatment of diabetic macular edema and diabetic retinopathy, respectively, met their primary endpoints and demonstrated positive safety results.
“We believe that with the increased surgical training, experience and techniques, and with the manufacturing process improvements for both the implant and the refill exchange needle, that we will be in good shape to hope to offer this to patients, both in clinical trials and commercially, toward the end of 2023,” Marcus said.
Collapse
Marcus D. Port Delivery System with ranibizumab (PDS) for continuous treatment in DME and DR: Additional results from the phase 3 Pagoda and Pavilion trials. Presented at: American Society of Retina Specialists annual meeting; July 28-Aug. 1, 2023; Seattle.
Read more about
Click Here to Manage Email Alerts